Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-01

Study Completion Date

2024-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators intend to conduct a single-center, prospective, randomized comparative trial of patients admitted to the intensive care unit (ICU) who received continuous glucose monitoring (CGM) vs point of care (POC) glucose monitoring. The study will examine relevant outcomes for patients in the ICU with diabetes mellitus and/or hyperglycemia. The primary outcome of the study will be the proportion of time in target range (blood glucose 70-180 mg/dL).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study of Intensive Care Unit Continuous Glucose Monitoring

NCT01301053

Hyperglycemia Hypoglycemia

UNKNOWN NA

Computerized Glucose Control in Critically Ill Patients

NCT01002482

Hyperglycemia Critical Illness

COMPLETED PHASE3

Continuous Glucose Monitoring (POC) in the ICU

NCT00464386

Burns Trauma

TERMINATED NA

Continuous Glucose Monitoring in Inpatients

NCT06329297

Hyperglycemia

NOT_YET_RECRUITING

Continuous Glucose Monitoring in Critically Ill Surgical Patients

NCT01108640

Hyperglycemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Purpose:

The purpose of this study is to compare the use of continuous glucose monitoring (CGM) versus point of care (POC) glucose monitoring in the intensive care unit (ICU) setting for differences in glycemic control and other important outcomes.

Research Plan:

This will be a prospective, single-center, randomized comparative trial of adult patients at North Florida/South Georgia Veterans Health System anticipated to be admitted to an ICU for a minimum of 48 hours after enrollment. Study participants will be randomly assigned to one of the study groups (CGM or POC) after being found eligible for inclusion and giving consent to participate. The CGM group will receive glycemic management based on CGM readings. The POC group will receive glycemic management based on POC glucose readings.

Study Outcomes:

Groups will be compared for differences in clinical and safety outcomes. The primary outcome will be the proportion of time in target range (BG 70-180mg/dL). Secondary outcomes will include mean glucose, hypoglycemia, hyperglycemia, ICU length of stay, mortality, glucose variability, cost, and patient satisfaction. Safety outcomes will include new infection, acute kidney injury, delirium, agitation, and pain.

Analysis Methods:

Descriptive statistics and inferential statistical methods will be used as appropriate to report findings of this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperglycemia Hypoglycemia Critical Illness Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Continuous Glucose Monitoring

Study subjects in this arm will receive glycemic management based on continuous glucose monitoring with CGM device. CGM readings will be available to patients, nurses, and the treating team. All treatment decisions for this group will be based on CGM readings, confirmatory POC readings (as necessary), and venipuncture.

Group Type ACTIVE_COMPARATOR

Continuous glucose monitoring

Intervention Type DEVICE

Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.

Point of Care Glucose Monitoring

Study subjects in this arm will receive glycemic management based on point of care blood glucose readings. CGM will be placed in blinded mode and used for study comparison only. Patients, nurses, and other treatment team will be blinded to the CGM readings. All treatment decisions for this group will be based on POC readings and venipuncture

Group Type ACTIVE_COMPARATOR

Point of care glucose monitoring

Intervention Type DEVICE

Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuous glucose monitoring

Continuous glucose monitoring involves a wearable device that measures glucose with a sensor that is inserted subcutaneously. The sensor transmits data to receiving device that displays the glucose values.

Intervention Type DEVICE

Point of care glucose monitoring

Point of care glucose monitoring involves use of an external device that can provide glucose readings at a patient's bedside. These devices require a small blood sample from venous, arterial, or capillary fingerstick blood. The blood sample is analyzed by the device and reports a glucose value within 5 minutes. This method of glucose monitoring is a mainstay and standard of care for most hospitals in the United States.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients age 18-89
* Past medical history of any diabetes mellitus OR patients with at least 1 measured BG of 180 being treated with insulin (subcutaneous or infusion)
* Enrollment will occur within 72 hours after being admitted to an ICU if history of diabetes
* Enrollment will occur within 72 hours after developing hyperglycemia in ICU if no diabetes

Exclusion Criteria

* Pregnant patients
* Patients using CGMs in the outpatient setting
* Diagnosis of diabetic ketoacidosis (DKA)
* Diagnosis of hyperosmolar hyperglycemic state (HHS)
* Anticipated to require prone positioning while on insulin therapy
* Any contraindications to CGMs based on manufacturer labeling
* BG above maximum reading for CGM (e.g. greater than 400 mg/dL)
* Receiving medication that could interfere with CGM readings (based on manufacturer specifications)
* Receiving any dose of hydroxyurea as this could falsely elevate the sensor readings (if applicable for specific CGM)
* Receiving greater than 1,000mg acetaminophen every 6 hours in any form as this could falsely elevate the sensor readings (if applicable for specific CGM)

Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No